1073 related articles for article (PubMed ID: 22862289)
1. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Li G; Hu W; Wang J; Deng X; Zhang P; Zhang X; Xie C; Wu S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1407-12. PubMed ID: 20350790
[TBL] [Abstract][Full Text] [Related]
3. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
[TBL] [Abstract][Full Text] [Related]
4. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
[TBL] [Abstract][Full Text] [Related]
6. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
9. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
Ren XJ; Wang L; Han C; Liu LL
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
[No Abstract] [Full Text] [Related]
11. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
15. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Iyer R; Chhatrala R; Shefter T; Yang G; Malhotra U; Tan W; Levea C; Robins M; Khushalani N
Oncology; 2013; 85(1):53-8. PubMed ID: 23860007
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Cho SH; Shim HJ; Lee SR; Ahn JS; Yang DH; Kim YK; Nam TK; Lee JJ; Kim HJ; Chung IJ
Dis Esophagus; 2008; 21(8):697-703. PubMed ID: 18522639
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
